Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sucampo Pharma Americas, LLC
Age
40–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is more than 40 and less than 70 years of age.
Patient has confirmed osteoarthritis (OA) and/or rheumatoid arthritis (RA) and could benefit from NSAID therapy.
No current gastrointestinal H. pylori infection.
You may not be if
Known allergy or hypersensitivity to NSAIDs, or has any other contraindicated condition(s) to NSAID therapy.
Patient has undergone a gastrointestinal or abdominal surgical procedure within 90 days prior to the Screening Visit, or has had a bowel resection at any time.
Medical history includes prior or active GI complications and/or disorders, including but not limited to Barrett's esophagus, erosive esophagitis, esophageal stricture or ring, gastric obstruction, irritable bowel syndrome (IBS), or inflammatory bowel disease (IBD).
Active symptomatic peptic ulcer disease or GI bleeding.
Patient has received cobiprostone (SPI-8811; RU-8811) or AMITIZA (other names: lubiprostone, SPI-0211, or RU-0211) at any time prior to participation in this study.
Clareo Health | Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
